Sapacitabine (CYC682)

  Cat. No.:  DC10444   Featured
Chemical Structure
151823-14-2
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Sapacitabine is an orally bioavailable pyrimidine analogue prodrug with potential antineoplastic activity.
Cas No.: 151823-14-2
Synonyms: CYC 682, CYC-682, CS-682, CS682, CS 682
SMILES: CCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)C#N
Formula: C26H42N4O5
M.Wt: 490.63
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Sapacitabine is unique in that it is an orally available nucleoside analog prodrug of CNDAC that acts through a dual mechanism. As a prodrug, it exhibits the therapeutic effect upon being metabolized; CNDAC lasts longer in the bloodstream by being metabolized from sapacitibine than by being directly administered. The compound interferes with DNA synthesis by causing single-strand DNA breaks due to CNDAC being incorporated into DNA during replication or repair,then inducing arrest of the cell division cycle at G2 phase.oth sapacitabine and its major metabolite, CNDAC, have demonstrated potent anti-tumor activity in both blood and solid tumors in preclinical studies. In a liver metastatic mouse model, sapacitabine was shown to be superior to gemcitabine (Gemzar; Lilly) or 5-FU, two widely used nucleoside analogs, in delaying the onset and growth of liver metastasis.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC10444 Sapacitabine (CYC682) Sapacitabine is an orally bioavailable pyrimidine analogue prodrug with potential antineoplastic activity.
X